Sponsor Pipeline

Gracell Biotechnologies (Shanghai) Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
3
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-24 NCT07250269
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With…		 Primary endpoint(s) modified
Active Trials by Phase
Phase 1/2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06235229 A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma Multiple Myeloma Recruiting
NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus Refractory Systemic Lupus Erythematosus Active, Not Recruiting
Phase 1
NCT07250269 Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With… Relapsed/Refractory AL Amyloidosis Recruiting
Disease Areas
Multiple Myeloma (1) Lupus (SLE) (1) Amyloidosis (1)
Get alerts when Gracell Biotechnologies (Shanghai) Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free